PL2328414T3 - Podstawione pochodne triazolo-pirydazyny - Google Patents

Podstawione pochodne triazolo-pirydazyny

Info

Publication number
PL2328414T3
PL2328414T3 PL09810685T PL09810685T PL2328414T3 PL 2328414 T3 PL2328414 T3 PL 2328414T3 PL 09810685 T PL09810685 T PL 09810685T PL 09810685 T PL09810685 T PL 09810685T PL 2328414 T3 PL2328414 T3 PL 2328414T3
Authority
PL
Poland
Prior art keywords
pyridazine derivatives
substituted triazolo
triazolo
substituted
pyridazine
Prior art date
Application number
PL09810685T
Other languages
English (en)
Polish (pl)
Inventor
Scott Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of PL2328414T3 publication Critical patent/PL2328414T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09810685T 2008-08-29 2009-08-28 Podstawione pochodne triazolo-pirydazyny PL2328414T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9329308P 2008-08-29 2008-08-29
PCT/US2009/055427 WO2010025407A1 (en) 2008-08-29 2009-08-28 Substituted triazolo-pyridazine derivatives
EP20090810685 EP2328414B1 (en) 2008-08-29 2009-08-28 Substituted triazolo-pyridazine derivatives

Publications (1)

Publication Number Publication Date
PL2328414T3 true PL2328414T3 (pl) 2014-05-30

Family

ID=41721962

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09810685T PL2328414T3 (pl) 2008-08-29 2009-08-28 Podstawione pochodne triazolo-pirydazyny

Country Status (17)

Country Link
US (4) US8003646B2 (enExample)
EP (2) EP2328414B1 (enExample)
JP (3) JP5183808B2 (enExample)
KR (1) KR20110063479A (enExample)
CN (2) CN102176826B (enExample)
AU (1) AU2009285533B2 (enExample)
BR (1) BRPI0912928A2 (enExample)
CA (1) CA2735549A1 (enExample)
DK (1) DK2328414T3 (enExample)
EA (1) EA020071B1 (enExample)
ES (1) ES2451542T3 (enExample)
HR (1) HRP20140195T1 (enExample)
MX (1) MX2011002278A (enExample)
PL (1) PL2328414T3 (enExample)
PT (1) PT2328414E (enExample)
WO (1) WO2010025407A1 (enExample)
ZA (1) ZA201102123B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2451542T3 (es) * 2008-08-29 2014-03-27 Concert Pharmaceuticals Inc. Derivados de triazolo-piridazina sustituidos
WO2010037194A1 (pt) 2008-10-03 2010-04-08 Instituto Alberto Luiz De Coimbra De Pós Graduação E Pesquisa De Engenharia - Coppe/Ufrj Dispositivo para remoção de fragmentos metálicos e elementos metálicos do interior de canáis radiculares de dentes e processo para remoção dos mesmos
US8501738B2 (en) * 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
EP2768834B1 (en) * 2011-10-20 2016-04-27 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2013104705A1 (de) 2012-01-11 2013-07-18 Bayer Intellectual Property Gmbh Tetrazol-5-yl- und triazol-5-yl-arylverbindungen und ihre verwendung als herbizide
US20150119398A1 (en) * 2012-05-11 2015-04-30 Concert Pharmaceuticals Inc. Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2013170241A1 (en) * 2012-05-11 2013-11-14 Concert Pharmaceuticals, Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
CN104474549A (zh) * 2014-11-24 2015-04-01 王寿世 异丙酚和gabaa受体拮抗剂在制备麻醉药物中的用途
CN104353078B (zh) * 2014-11-24 2017-10-24 王寿世 一种麻醉用药物组合物
US10026332B1 (en) 2017-04-10 2018-07-17 Jasmine Gupta Method to deliver contextual educational information utilizing smart wearables
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain
JP2025513560A (ja) * 2022-04-20 2025-04-24 エングレイル セラピューティクス，インコーポレーテッド Ｇａｂａａ受容体モジュレーター塩、粒子、およびその使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) * 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
AU723098B2 (en) 1996-07-25 2000-08-17 Merck Sharp & Dohme Limited Substituted triazolo-pyridazine derivatives as ligands for GABA receptors
AU748737B2 (en) * 1998-01-21 2002-06-13 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for GABA receptors
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1149102B1 (en) * 1999-01-27 2004-12-08 MERCK SHARP & DOHME LTD. Triazolo-pyridazine derivatives as ligands for gaba receptors
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP4426461B2 (ja) * 2002-11-28 2010-03-03 ニューロサーチ、アクティーゼルスカブ 鎮静薬または抗不安薬としての効力を有する化合物をスクリーニングする方法
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008122020A1 (en) * 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
ES2451542T3 (es) * 2008-08-29 2014-03-27 Concert Pharmaceuticals Inc. Derivados de triazolo-piridazina sustituidos

Also Published As

Publication number Publication date
JP5183808B2 (ja) 2013-04-17
EP2328414B1 (en) 2013-12-11
DK2328414T3 (en) 2014-03-10
HRP20140195T1 (hr) 2014-04-11
EP2716158A1 (en) 2014-04-09
US20120004236A1 (en) 2012-01-05
JP2013100322A (ja) 2013-05-23
JP2012501346A (ja) 2012-01-19
JP2014058518A (ja) 2014-04-03
WO2010025407A1 (en) 2010-03-04
CN102176826B (zh) 2014-08-20
US20130225590A1 (en) 2013-08-29
CN104098578A (zh) 2014-10-15
EA020071B1 (ru) 2014-08-29
CA2735549A1 (en) 2010-03-04
EP2328414A1 (en) 2011-06-08
US20100056529A1 (en) 2010-03-04
CN102176826A (zh) 2011-09-07
AU2009285533A1 (en) 2010-03-04
MX2011002278A (es) 2011-04-14
JP5373982B2 (ja) 2013-12-18
US8399467B2 (en) 2013-03-19
US8921366B2 (en) 2014-12-30
EA201100409A1 (ru) 2011-10-31
EP2328414A4 (en) 2011-11-16
PT2328414E (pt) 2014-03-17
US20150111895A1 (en) 2015-04-23
US8003646B2 (en) 2011-08-23
KR20110063479A (ko) 2011-06-10
BRPI0912928A2 (pt) 2015-08-04
AU2009285533B2 (en) 2014-02-13
ES2451542T3 (es) 2014-03-27
ZA201102123B (en) 2011-12-28
AU2009285533A2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
ZA201102123B (en) Substituted triazolo-pyridazine derivatives
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
IL205759A0 (en) Isoxazolo-pyridine derivatives
IL205753A0 (en) Isoxazolo-pyridazine derivatives
ZA201102449B (en) Morpholinopurine derivatives
IL202020A0 (en) Spiroindolinone derivatives
ZA201006104B (en) Substituted xanthine derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
IL202830A0 (en) Indazolamide derivatives
IL205755A0 (en) Isoxazolo-pyrazine derivatives
IL210172A0 (en) Substituted pyrimidin-4-one derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
IL211241A0 (en) 7-azaindole derivatives
ZA201101236B (en) New 2-amidothiadiazole derivatives
ZA201100948B (en) Acylaminobenzamide derivatives
IL213424A0 (en) Quinazolinamide derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
IL207192A0 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
IL202667A0 (en) Isoxazole-imidazole derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives